Not sure if this has been posted yet, but the key point of this new study is that phenethylamines produce more tolerance than tryptamines. The chemicals studied were DOI, 2C-T-7, DPT, and DIPT.
Source:
http://www.ncbi.nlm.nih.gov/pubmed/25271256
J Pharmacol Exp Ther. 2014 Sep 30.
Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.
Abstract
The serotonin 5-HT2A receptor is a potential therapeutic target to a host of neuropsychiatric conditions, but agonist actions at this site are linked to abuse-related hallucinogenic effects which may limit therapeutic efficacy of chronic drug administration. Tolerance to some effects of hallucinogens have been observed in humans and laboratory animals, but the understanding of tolerance and cross-tolerance between distinct structural classes of hallucinogens is limited. Here we used the drug-elicited head twitch response (HTR) in mice to assess the development of tolerance and cross-tolerance with two phenethylamine-derived (2,5-dimethoxy-4-iodoamphetamine [DOI] and 2,5-dimethoxy-4-propylthiophenethylamine [2C-T-7]) and two tryptamine-derived (N,N-dipropyltryptamine [DPT] and N,N-diisopropyltryptamine [DIPT]) drugs with agonist affinity for 5-HT2A receptors. Tolerance developed to HTR elicited by daily DOI or 2C-T-7, but not to HTR elicited by DPT or DIPT. DOI-elicited tolerance was not surmountable with dose, and a similar insurmountable cross-tolerance was evident when DOI-tolerant mice were tested with various doses of 2C-T-7 or DPT. These studies suggest that the use of phenethylamine-derived hallucinogens as therapeutic agents may be limited not only by their abuse potential, but also by the rapid development of tolerance which would likely be maintained even if a patient were switched to a different 5-HT2A agonist medication from a distinct structural class. However, these experiments also imply that tryptamine-derived hallucinogens might have a reduced potential for tolerance development, as compared to phenethylamine-derived 5-HT2A agonists, and might therefore be more suitable for chronic administration in a therapeutic context.
PMID: 25271256 [PubMed - as supplied by publisher]
Source:
http://www.ncbi.nlm.nih.gov/pubmed/25271256
J Pharmacol Exp Ther. 2014 Sep 30.
Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.
Abstract
The serotonin 5-HT2A receptor is a potential therapeutic target to a host of neuropsychiatric conditions, but agonist actions at this site are linked to abuse-related hallucinogenic effects which may limit therapeutic efficacy of chronic drug administration. Tolerance to some effects of hallucinogens have been observed in humans and laboratory animals, but the understanding of tolerance and cross-tolerance between distinct structural classes of hallucinogens is limited. Here we used the drug-elicited head twitch response (HTR) in mice to assess the development of tolerance and cross-tolerance with two phenethylamine-derived (2,5-dimethoxy-4-iodoamphetamine [DOI] and 2,5-dimethoxy-4-propylthiophenethylamine [2C-T-7]) and two tryptamine-derived (N,N-dipropyltryptamine [DPT] and N,N-diisopropyltryptamine [DIPT]) drugs with agonist affinity for 5-HT2A receptors. Tolerance developed to HTR elicited by daily DOI or 2C-T-7, but not to HTR elicited by DPT or DIPT. DOI-elicited tolerance was not surmountable with dose, and a similar insurmountable cross-tolerance was evident when DOI-tolerant mice were tested with various doses of 2C-T-7 or DPT. These studies suggest that the use of phenethylamine-derived hallucinogens as therapeutic agents may be limited not only by their abuse potential, but also by the rapid development of tolerance which would likely be maintained even if a patient were switched to a different 5-HT2A agonist medication from a distinct structural class. However, these experiments also imply that tryptamine-derived hallucinogens might have a reduced potential for tolerance development, as compared to phenethylamine-derived 5-HT2A agonists, and might therefore be more suitable for chronic administration in a therapeutic context.
PMID: 25271256 [PubMed - as supplied by publisher]